Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). · 2018
Read Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. by Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5757427.txt.
Introduction
The Early Breast Cancer Trialists' Collaborative Group pools patient data from ten trials on chemo timing. The trials compared chemo before surgery with the same chemo after surgery. They covered 4,756 women with early breast cancer. Follow-up ran a median of nine years.
Chemo before surgery shrank most tumors, the group reports. It raised the rate of breast conserving surgery from 49% to 65%. Local return of cancer was more common after early chemo, though. At 15 years it stood at 21.4% against 15.9%. Distant spread and death rates did not differ between the two paths.
Catalog record
| CREATOR | Early Breast Cancer Trialists' Collaborative Group (EBCTCG). |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials Published in: The Lancet. Oncology DOI: 10.1016/S1470-2045(17)30777-5 ABSTRACT Summary Background Neoadjuvant chemotherapy (NACT) for early breast cancer can make breast-conserving surgery more feasible and might be more likely to eradicate micrometastatic disease than might the same chemotherapy given after surgery. We investigated the long-term benefits and risks of NACT and the influence of tumour characteristics on outcome with a collaborative meta-analysis of individual patient data from relevant randomised trials. Methods We obtained information about prerandomisation tumour characteristics, clinical tumour response, surgery, recurrence, and mortality for 4756 women in ten randomised trials in early breast cancer that began before 2005 and compared NACT with the same chemotherapy given postoperatively. Primary outcomes were tumour response, extent of local therapy, local and distant recurrence, breast cancer death, and overall mortality. Analyses by intention-to-treat used standard regression (for response and frequency of breast-conserving therapy) and log-rank methods (for recurrence and mortality). Findings Patients entered the trials from 1983 to 2002 and median follow-up was 9 years (IQR 5–14), with the last follow-up in 2013. Most chemotherapy was anthracycline based (3838 [81%] of 4756 women). More than two thirds (1349 [69%] of 1947) of women allocated NACT had a complete or partial clinical response. Patients allocated NACT had an increased frequency of breast-conserving therapy (1504 [65%] of 2320 treated with NACT vs 1135 [49%] of 2318 treated with adjuvant chemotherapy). NACT was associated with more frequent local recurrence than was adjuvant chemotherapy: the 15 year local recurrence was 21·4% for NACT versus 15·9% for adjuvant chemotherapy (5·5% increase [95% CI 2·4–8·6]; rate ratio 1·37 [95% CI 1·17–1·61]; p=0·0001). No significant difference between NACT and adjuvant chemotherapy was noted for distant recurrence (15 year risk 38·2% for NACT vs 38·0% for adjuvant chemotherapy; rate ratio 1·02 [95% CI 0·92–1·14]; p=0·66), breast cancer mortality (34·4% vs 33·7%; 1·06 [0·95–1·18]; p=0·31), or death from any cause (40·9% vs 41·2%; 1·04 [0·94–1·15]; p=0·45). Interpretation Tumours downsized by NACT might have higher local recurrence after breast-conserving therapy than might tumours of the same dimensions in women who have not received NACT. Strategies to mitigate the increased local recurrence after breast-conserving therapy in tumours downsized by NACT should be considered—eg, careful tumour localisation, detailed pathological assessment, and appropriate radiotherapy. Funding Cancer Research UK, British Heart Foundation, UK Medical Research Council, and UK Department of Health. INTRODUCTION Neoadjuvant chemotherapy (NACT)—ie, chemotherapy begun before breast cancer surgery—was introduced in the 1970s,1 aiming to downstage locally advanced (inoperable) disease and make it operable. NACT was subsequently extended to operable (early) breast cancer, mainly to allow breast-conserving surgery, and is now widely used, particularly for large tumours.2, 3, 4 Furthermore, NACT might be somewhat more likely to eradicate micrometastatic disease than might chemotherapy delayed until after surgery. NACT might mitigate the hypothesised stimulatory effect of surgery on occult disease5 and reduce tumour cell shedding during surgery. NACT might also provide useful in-vivo information about the chemosensitivity of the local (and, by implication, disseminated) tumour to different chemotherapy regimens, helping to guide subsequent drug selection.6, 7 Conversely, by delaying surgery, NACT might increase the risk of metastatic spread, particularly for chemoresistant tumours. Several randomised trials8, 9, 10, 11, 12, 13, 14, 15, 16, 17 have compared NACT with the same chemotherapy given postoperatively. Interpretation of these trials is complicated, however, as the frequency of breast-conserving surgery often differed between groups because of tumour shrinkage after NACT. In certain trials,14, 15 some good responders to NACT did not receive surgery, and high frequencies of local recurrence with NACT in these trials have been attributed to omission of definitive local therapy. Any such differences in the extent of surgery confound comparisons of the efficacy of NACT with that of adjuvant chemotherapy.18, 19 Another complication is that investigations of the influence of tumour characteristics on outcome need to use prerandomisation data, as analyses by postsurgical characteristics would be substantially biased by downstaging.20 To investigate such issues in more detail than was possible in reviews18, 19 of published data, we did a patient-level meta-analysis of the trials that directly compared any NACT regimen with the same regimen begun postoperatively. Research in contextEvidence before this studyThe Early Breast Cancer Trialists' Collaborative Group's ongoing extensive searches of bibliographic databases, including MEDLINE, Embase, the Cochrane Library, and meeting abstracts up to March 2017, identified 16 trials that compared neoadjuvant chemotherapy (NACT) with the same chemotherapy postoperatively. Meta-analyses of published reports indicate that NACT reduced the frequency of mastectomy but did not affect mortality. Interpretation is complicated, however, as the use of breast-conserving surgery often differed between groups because of tumour shrinkage by NACT. In certain trials, some patients with a good response did not receive surgery. Hence, women allocated NACT retained more breast tissue than did those allocated adjuvant chemotherapy, and higher local recurrence frequencies in some neoadjuvant trials than in others have been attributed to omission of definitive local therapy.Added value of this studyWe did a meta-analysis of individual patient data from trials that compared NACT with the same chemotherapy given postoperatively. We assessed effects of patient and tumour characteristics on tumour response, extent of local therapy, local and distant recurrence, breast cancer death, and overall mortality. This individual patient data meta-analysis, involving 4756 women in ten trials, found that the frequencies of clinical response and breast-conserving therapy were higher for smaller, higher-grade, and oestrogen receptor-negative and progesterone receptor-negative tumours, and for one trial using anthracycline and taxane chemotherapy. Although responders to NACT had lower distant recurrence and breast cancer mortality than did non-responders, when responders and non-responders were combined, distant recurrence and breast cancer mortality were similar for NACT and adjuvant chemotherapy. Local recurrence was, however, higher with NACT than with adjuvant chemotherapy, which persisted for 10 years after treatment and was not confined to trials in which surgery could be omitted after response to NACT.Implications of all the available evidenceNACT is as effective as adjuvant chemotherapy in reducing the risk of distant recurrence and death from breast cancer. However, NACT is associated with higher local recurrence than adjuvant chemotherapy, which could be at least partly explained by wider use of breast-conserving therapy after NACT than with postoperative chemotherapy. Strategies to mitigate the increased local recurrence after breast-conserving therapy in tumours downsized by NACT should be considered—eg, careful tumour localisation, detailed pathological assessment, and appropriate radiotherapy. METHODS Study design and participants We sought data from all randomised trials in early (ie, operable) breast cancer that began before 2005 and compared NACT with the same chemotherapy begun after surgery (ie, standard adjuvant chemotherapy). NACT always started before surgery, although in some trials, some of the chemotherapy in the NACT group was given postoperatively, whereas all chemotherapy in the control group had to be postoperative (so trials such as NSABP B-2721 were ineligible). Trial identification and data checking were as reported previously22, 23 and conformed to the Preferred Reporting Items for Systematic Review and Meta-Analyses (Individual Patient Data).24 For every woman, we requested information from the trial's principal investigator or another appropriate member of their research group about patient and tumour characteristics, treatments, dates of any local recurrence (breast, chest wall, or regional